Clinical Trials Logo

Diabetic Nephropathy clinical trials

View clinical trials related to Diabetic Nephropathy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05061459 Not yet recruiting - Clinical trials for Diabetic Nephropathy

The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy

Start date: October 2021
Phase:
Study type: Observational

1. To evaluate expression levels of circANKRD36 in the development and progression of DN. 2. To investigate correlation between expression levels of circANKRD36 and stages of DN. 3. To investigate correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in T2DM patients with CKD.

NCT ID: NCT03658317 Not yet recruiting - Clinical trials for Diabetic Nephropathy

Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy

Start date: September 2018
Phase: N/A
Study type: Interventional

diabetic nephropathy is one of the leading causes of end stage renal disease

NCT ID: NCT01725412 Not yet recruiting - Clinical trials for Diabetic Nephropathy

Prevention of Renal Complications of Diabetes With Thiamine

Start date: November 2012
Phase: Phase 4
Study type: Interventional

Thiamine is a key component in the creation of physiologic anti-inflammatory mediators. Serum thiamine stores have been found to be deficient in diabetic patients. Thiamine deficiency may be a key pathological mechanism of inflammation that results in diabetic kidney and retinal injury. The investigators hypothesize that the repletion of a patient's thiamine by oral supplementation may result in reduced inflammation, and therefore reduced kidney injury.

NCT ID: NCT01566006 Not yet recruiting - Clinical trials for Chronic Kidney Disease

Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration

Myridian
Start date: April 2012
Phase: N/A
Study type: Interventional

Diabetes mellitus (DM) is a growing disease and it is a public health concern, and projections of its future effect are alarming. About one third of those affected will develop diabetic nephropathy at 20 years after diagnosis. Of these patients, 20% will develop clinically end-stage renal disease ESRD, requiring renal replacement therapy (RRT). Patients with type 2 diabetes account for most patients with end stage renal disease (ESRD) and RRT. To the best of the investigators knowledge, the effects of MMF on diabetic nephropathy in patients with DM type II were not studied so far. Therefore, the purpose of this pilot study is to evaluate the effects of Mofetil Mycophenolate (MMF) on proteinuria and progression of kidney disease of diabetic origin, in patients at high risk for progressive renal failure in whom other treatment modalities are insufficient or had failed.

NCT ID: NCT00497666 Not yet recruiting - Diabetes Clinical Trials

Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

Start date: August 2007
Phase: N/A
Study type: Observational

Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy. We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.